Previous studies have demonstrated that treatment of TLR9-expressing cancer cells with synthetic TLR9 ligands, which mimic the structure of bacterial DNA, stimulates their invasion in vitro through matrix metalloproteinase-13 (MMP-13) activation (6,12,13). Here, MMP13 is linked to cancer.